KLONOPIN WAFERS

Compare KLONOPIN WAFERS  to:
Compare
Compare

Generic Name for KLONOPIN WAFERS

Clonazepam 0.125mg, 0.25mg, 0.5mg, 1mg, 2mg; orally-disintegrating tabs.

Legal Classification:

CIV

Pharmacological Class for KLONOPIN WAFERS

Benzodiazepine.

Manufacturer of KLONOPIN WAFERS

Roche Laboratories

Indications for KLONOPIN WAFERS

Panic disorder.

Adult dose for KLONOPIN WAFERS

>18yrs: initially 0.25mg twice daily; after 3 days increase to 1mg/day; then may increase every 3 days by 0.125–0.25mg twice daily; max 4mg/day. Wafers: dissolve in mouth; swallow with or without water.

Children's dosing for KLONOPIN WAFERS

<18yrs: not recommended.

Also:

Contraindications for KLONOPIN WAFERS

Significant liver disease. Acute narrow-angle glaucoma.

Precautions for KLONOPIN WAFERS

Suicidal tendencies (monitor). Chronic respiratory disease. Renal impairment. Avoid abrupt cessation. Reevaluate periodically. Monitor blood counts, liver function. Elderly. Labor & delivery, pregnancy (Cat.D), nursing mothers: not recommended.

Interactions for KLONOPIN WAFERS

Potentiates CNS depression with alcohol, other CNS depressants. Adjust anticonvulsants if needed. Absence seizures with valproate. Caution with drugs that inhibit CYP3A (eg, azole antifungals). Antagonized by CYP450 inducers (eg, phenytoin, carbamazepine, phenobarbital). Wafers may be antagonized by propantheline.

Adverse Reactions for KLONOPIN WAFERS

CNS effects (esp. depression), hypersalivation, liver disorders, GI upset, blood dyscrasias, paradoxical reactions.

How is KLONOPIN WAFERS supplied?

Tabs—100
Wafers—60

Related Disease:

Panic disorder

Related Resources

Exel/Exelint infusion set needles recalled

January 26, 2010

FDA notified healthcare professionals of a Class I recall of Exel/Exelint Huber needles, Exel/Exelint Huber Infusion Sets, and Exel/Exelint "Securetouch+" Safety Huber Infusion Sets due to 'coring,' the cutting or dislodging of silicone cores or slivers from the ports into which they are inserted).

Cymbalta approved for maintenance treatment of generalized anxiety disorder (GAD)

November 30, 2009

The FDA has approved Cymbalta (duloxetine HCl, from Lilly) for the maintenance treatment of generalized anxiety disorder (GAD) in adults.

Once-daily venlafaxine extended-release tablets available

August 19, 2009

Osmotica Pharmaceutical and Upstate Pharma, a subsidiary of UCB, have made available venlafaxine extended-release tablets in 37.5mg, 75mg, 150mg, and 225mg dosage strengths.

FDA approves updated labeling for antiepileptic drugs

May 05, 2009

The FDA has approved updated labeling for antiepileptic drugs used to treat epilepsy, psychiatric disorders, and other conditions (eg, migraines, neuropathic pain syndromes).

FDA halts marketing of unapproved nitroglycerin tablets

March 17, 2010

The FDA has ordered Glenmark Generics and Konec Inc. to stop marketing unapproved nitroglycerin tablets.